Premium
The acute myeloid leukemia‐associated Nucleophosmin 1 gene mutations dictate amyloidogenicity of the C‐terminal domain
Author(s) -
La Manna Sara,
Scognamiglio Pasqualina Liana,
Roviello Valentina,
Borbone Fabio,
Florio Daniele,
Di Natale Concetta,
Bigi Alessandra,
Cecchi Cristina,
Cascella Roberta,
Giannini Cinzia,
Sibillano Teresa,
Novellino Ettore,
Marasco Daniela
Publication year - 2019
Publication title -
the febs journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 204
eISSN - 1742-4658
pISSN - 1742-464X
DOI - 10.1111/febs.14815
Subject(s) - npm1 , nucleophosmin , myeloid leukemia , mutant , k562 cells , mutation , gene mutation , amyloid (mycology) , biology , cancer research , gene , point mutation , leukemia , chemistry , genetics , botany , karyotype , chromosome
Nucleophosmin 1 (NPM1) is a nucleus‐cytoplasm shuttling protein ubiquitously expressed and highly conserved. It is involved in many cellular processes and its gene is mutated in ~ 50–60% of Acute Myeloid Leukemia (AML) patients. These mutations cause its cytoplasmic mislocation and accumulation (referred to as NPM1c+) and open the door to rational targeted therapy for AML diseases with mutated NPM1 . Currently, there is limited knowledge on the mechanism of action of NPM1c+ and on structural determinants of the leukemogenic potential of AML mutations. Numerous previous studies outlined an unexpected amyloid‐like aggregation tendency of several regions located in the C‐terminal domain that, in wild‐type form, fold as a three‐helical‐bundle. Here, using a combination of different techniques including Thioflavin T fluorescence, congo red absorbance, CD spectroscopy, Scanning Electron Microscopy (SEM) and wide‐angle X‐ray scattering on a series of peptides bearing mutations, we evidence that the amyloidogenicity of NPM1 mutants is directly linked to AML. Noticeably, AML point mutations strongly affect the amyloid cytotoxic effects in neuroblastoma cells and the morphologies of deriving fibrils. This study paves the way to deepen our understanding of AML‐associated NPM1 mutants, and could help to break new ground for the identification of novel drugs targeting NPM1c+ for treatment of AML.